Triple meeting 2025 – early efficacy signs for Quanta
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
Another pan-KRAS project enters the clinic
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
BeiGene takes a new approach to a hot target
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
